Sign up


Match Document Document Title
US20130244517 DECORATIVE PRODUCTS AND BUILDING PRODUCTS WITH IMPROVED OPACITY  
A decorative or building product in which one or more constituents of the product include melamine cyanurate in an amount effective to provide or enhance opacity in the product.
US20120308652 ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR  
The invention relates to pharmaceutical formulations, preferably in the form of an oral dosage form, for the treatment of chronic hepatitis-B virus infections, containing micronised Entecavir, and...
US20120135961 USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS  
The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological...
US20110160162 PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS  
Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.
US20120295919 ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS  
Provided are opioid receptor antagonists represented by the formula (I) where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.
US20130190340 Small-Molecule-Targeted Protein Degradation  
Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other...
US20110034495 Method of Modulating Stress-Activated Protein Kinase System  
A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are...
US20110288105 ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA  
The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in...
US20140243523 HUMAN EPITHELIAL CELL LINE FOR 3-D MODELIZING OF CANCER AND TREATMENT THEREOF  
A cellular model is described that targets dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described, is a screening method using this cellular...
US20110136797 CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR  
Certain cyclopropyl amines are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
US20140234852 HUMAN KERATINOCYTES PTCH1 CELL LINE  
A cellular model is described for targeting dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described, is a screening method using this cellular...
US20120184556 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS  
Disclosed are substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators.
US20130288250 SIGNATURES OF CLINICAL OUTCOME IN GASTRO INTESTINAL STROMAL TUMORS AND METHOD OF TREATMENT OF GASTROINTESTINAL STROMAL TUMORS  
A method for in vitro predicting survival and/or metastatic outcome of gastrointestinal stromal tumors (GISTs), characterized in that it comprises the measure of the level, in a patient-derived...
US20140000807 ACCELERATORS FOR TWO STEP ADHESIVE SYSTEMS  
Benzoylthiourea or benzoylthiourethane derivatives as cure accelerators in primers for two step adhesive systems are provided.
US20130259800 COMPOSITIONS AND METHODS FOR CANCER TREATMENT  
The invention described herein pertains to the use of oxazolidinone antibiotics, alone or in combination, in the treatment of cancer. In particular, the invention pertains to the treatment of...
US20110172243 USE OF AZAPERONE FOR REDUCING ANTIBIOTIC USAGE  
The present invention relates to a method for the reduction of antibiotic usage in animals through the use of orally administered azaperone.
US20120315217 INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR  
TSHR inverse agonists and neutral antagonists that are useful for treating Graves' orbitopathy, Graves' hyperthyroidism and/or thyroid cancer.
US20120028907 METHODS FOR IDENTIFICATION OF TUMOR PHENOTYPE AND TREATMENT  
The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a...
US20130324409 CONTROL OF PLANT STRESS TOLERANCE, WATER USE EFFICIENCY AND GENE EXPRESSION USING NOVEL ABA RECEPTOR PROTEINS AND SYNTHETIC AGONISTS  
The present invention provides methods of regulating plant stress tolerance.
US20110318345 NASAL DELIVERY  
substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of...
US20140302120 CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR  
The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
US20120148660 CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR  
The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
US20140038967 NOVEL USE FOR IMIDAZOTRIAZINONES  
Provided herein are compounds for use in the treatment of central nervous system (CNS)-trauma related disorders like spinal cord injuries. Pharmaceutical compositions, single unit dosage forms, and...
US20130236504 Delivery System for Enhancing Drug Efficacy  
Disclosed are delivery systems that can be used for treating cancer. The delivery systems include a delivery vehicle in conjunction with a chemo-adjuvant. The chemo-adjuvant can enhance the...
US20130143889 Heterocycles As Potassium Channel Modulators  
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More...
US20110086818 METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS  
The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while...
US20140107568 METHOD OF DETERMINING AN INJECTED DOSE BASED ON A KNOWN ORAL DOSE  
The present disclosure relates to methods of determining dosages of compositions used in injection devices, in view of known oral doses of the same compositions.
US20140099662 PHOTOTOXICITY TEST METHOD  
The present invention provides a phototoxicity test method using human retinal pigment epithelial cells, and so on.
US20130123283 METHODS AND COMPOSTIONS FOR TREATING PAIN  
The present application relates to compounds and methods for treating pain, incontinence and other conditions.
US20120064181 P2X3 Receptor Antagonists for Treatment of Pain  
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
US20120015052 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN  
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
US20110206783 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN  
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
US20110003822 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN  
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
US20140309192 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO  
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof: that are useful in methods of treatment and alleviation of diseases...
US20130224114 Translocator Protein Ligands  
The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the...
US20110044898 TRANSLOCATOR PROTEIN LIGANDS  
The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the...
US20120259154 In Vivo Immunomagnetic Hyperthermia Platform for Any Cell or Virus Having a Target Surface Receptor  
The invention is a nano-entity conjugate for use in an in vivo immunomagnetic hyperthermia system for the detection and treatment of any cell or virus having a target surface receptor which...
US20110201602 PROTEIN KINASE MODULATORS AND METHOD OF USE  
The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating...
US20110244486 METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES  
Methods, assays and compositions for the diagnosis and treatment of diabetes, in which the glutamate transporters and/or receptors expressed in pancreatic islet cells are used as therapeutic...
US20140121205 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME  
Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related...
US20140121197 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME  
Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related...
US20130252936 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME  
Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related...
US20110213145 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners  
The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with...
US20110183995 ELTOPRAZINE FOR SUPPRESSION OF L-DOPA INDUCED DYSKINESIAS  
This invention relates to the use of the drug Eltoprazine for combating dyskinesias arising from chronic Levodopa (L-DOPA) therapy in patients suffering from Parkinson's disease.
US20110230441 STABLE BORTEZOMIB FORMULATIONS  
Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid...
US20120121508 RADIOLABELED CGRP ANTAGONISTS  
The present invention is directed to radiolabeled CGRP receptor antagonists which are useful for the quantitative imaging of CGRP receptors in mammals.
US20140364604 METHOD OF MAKING MONOMETHYL FUMARATE  
Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are...
US20110110914 METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS  
Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
US20120101427 NOVEL PHOTOSENSITIZER FORMULATIONS FOR ORAL ADMINISTRATION  
The present invention provides novel drug formulations for oral administration for diverse medical applications including anticancer, antimetastatic, antibacterial, antifungal, antiprotozoic,...
US20120277180 Cofactors and Methods for Use for Individuals  
Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of...